Geneva, April 28 -- International Clinical Trials Registry received information related to the study (NCT07537946) titled 'Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer' on April 12.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Outcomes Assessor).
Primary Sponsor: Tongji Hospital
Condition:
Hepatocellular Carcinoma (HCC)
Metastases
Intervention:
Drug: Sintilimab
Drug: Lenvatinib
Recruitment Status: Not recruiting
Phase: Phase 3
Date of First Enrollment: May 30, 2026
Target Sample Size: 400
Countries of Recruitment:
China
To know more, visit https://clinicaltrials.gov/study/NCT075379...